Introduction
============

Colon cancer is one of the most commonly diagnosed cancers among both men and women in the United States.[@b1-cmar-10-2303] Presently, colon cancer is staged according to a system designed by the American Joint Committee on Cancer (AJCC) that defines the prognosis in a clear manner and is thus used for clinical treatment decisions. The AJCC staging system differentiated patients on the basis of the invasion extent of primary tumor (T-stage), lymph node status (N-stage), and distant spread (M-stage). However, the TNM staging system is not perfect for the prognostic prediction and clinical management of colon cancer. The AJCC issued a request for proposals to develop staging methods based on other available information beyond the classical TNM staging.[@b2-cmar-10-2303]

The present study focused on improving the AJCC TNM staging system. In 1990, Kune et al[@b3-cmar-10-2303] suggested that older patients with colon cancer might have worse survival compared with younger patients. In 1984, Phillips et al[@b4-cmar-10-2303] reported that the tumor grade was an independent prognostic factor in large bowel cancer. Also, Kornprat et al[@b5-cmar-10-2303] analyzed 359 patients with colon cancer and reported that the tumor size was significantly associated with progression-free and cancer-specific survival (CSS) and negatively impacted survival.

Moreover, many subsequent studies revealed that age at diagnosis,[@b6-cmar-10-2303]--[@b9-cmar-10-2303] tumor grade,[@b10-cmar-10-2303],[@b11-cmar-10-2303] and tumor size[@b12-cmar-10-2303],[@b13-cmar-10-2303] had a strong correlation with the prognosis of colon cancer. Yet most of them focus on the prognostic significance of one single factor and no study attempt to combine the three factors together for improved prognostic prediction. Therefore, this study proposed a novel prognostic score based on 3 patient and tumor characteristics, consequently obtaining the P-stage from the prognostic score. The present study analyzed the combined value of P-stage and the TNM staging system in predicting the prognosis and clinical management.

Patients and methods
====================

Study design and data source
----------------------------

The Surveillance, Epidemiology, and End Results (SEER) database is an authoritative source of information on cancer incidence and survival in the United States. This database provides a comprehensive source of population-based information including all newly diagnosed cancer cases among people residing in areas participating in the SEER program and covering approximately 28% of the US population.

As shown in [Figure 1](#f1-cmar-10-2303){ref-type="fig"}, data were obtained for 185,617 patients with a diagnosis of malignant colorectal cancer between January 1, 2010, and December 31, 2014, from the SEER program of the National Cancer Institute. Among these patients, 68,945 patients who satisfied the following inclusion criteria were identified: colon cancer, age, grade, tumor size, the seventh edition of TNM staging available, and 1 malignant primary tumor only. Patients with T0- or Tis-stage were excluded for an accurate staging. Patients with nonadenocarcinoma histology or unknown surgery status were also excluded. Finally, the target population included 56,800 colon cancer patients with diagnosis based on the seventh edition of TNM stage and 3 specific prognostic factors (age at diagnosis, tumor grade, and tumor size) available.

P-stage: risk-stratification
----------------------------

Patients were stratified based on a prognostic score incorporating 3 patient and tumor characteristics (age at diagnosis, tumor grade, and tumor size) that have been reported to influence the survival of colon cancer patients.[@b3-cmar-10-2303]--[@b8-cmar-10-2303],[@b10-cmar-10-2303]--[@b13-cmar-10-2303] As can be seen in [Figure 2](#f2-cmar-10-2303){ref-type="fig"}, we calculated the total score with 0, 1, 2, and 3 points each given for age (≤49, \>49--64, \>64--79, \>79 years), grade (well differentiated or grade I; moderately differentiated or grade II; poorly differentiated or grade III; undifferentiated, anaplastic or grade IV), and tumor size (≤2, \>2--4, \<4--6, \>6 cm). The total scores ranged from 0 to 9, then a comprehensive prognostic score based on the 3 prognostic factors was obtained, with a score of 0 having the best prognosis and those with a score of 9 having the worst prognosis. These cut points were based on the prior cohort studies concerning the prognostic factors of age at diagnosis,[@b7-cmar-10-2303] tumor grade,[@b11-cmar-10-2303] and tumor size.[@b13-cmar-10-2303] Finally, we got the P-stage of each patient according to the prognostic score -- score 0--4 was assigned to P0-stage and score 5--9 was assigned to P1-stage.

Statistical analyses
--------------------

Several Cox proportional hazards models were built to identify independent prognostic variables at a median survival time of 20 months (ranged 0--59 months). All the hazard ratios (HRs) are shown with 95% confidence interval (CI). The endpoint used for comparison in the present study was 59-month CSS based on selected patients with colon cancer because the longest follow-up time was 59 months, not \>5 years. Variables that showed prognostic significance (log-rank, *P*\<0.20) in the univariate analysis were included in the multivariate analysis of the selected patients. Moreover, the variables, including P-stage, TNM stage, tumor location, surgery status, histology, race, and year of diagnosis, were included in the multivariate analyses using Cox proportional hazards models. The TNM staging used in this study was the seventh edition of the AJCC cancer staging system, the newest TNM stage that could be obtained from the SEER database. This study also designed a variable called the "N--P stage," combining the N-stage (N0-, N1-, N2a-, and N2b-stage) and the P-stage (P0 and P1, based on the prognostic score), to compare the interaction between these 2 stages in patients with nonmetastatic colon cancer. The Kaplan--Meier survival curves were used to evaluate the prognostic prediction of different factors and the log-rank tests to assess the statistical significance. A *P*-value \<0.05 was considered statistically significant. A statistical analysis was performed using the SPSS version 22 (IBM Corporation, Armonk, NY, USA).

Ethics statement
================

The study was approved by the Ethical Committee and Institutional Review Board of the Fudan University Shanghai Cancer Center. The data did not include the use of human subjects or personal identifying information, and so no informed consent was required for this study.

Results
=======

P-stage was strongly associated with the survival of colon cancer
-----------------------------------------------------------------

The median follow-up time for the overall cohort was 20 months. At the end of the follow-up time, 8,841 (15.6%) patients died of colon cancer. [Table S1](#SD2-cmar-10-2303){ref-type="supplementary-material"} demonstrates that higher grade, larger tumor size, and older age are associated with poorer survival, which was consistent with a prior study.[@b14-cmar-10-2303] A multivariable analysis was conducted to identify the variables independently associated with CSS in the overall cohort, and it was found that the P1-stage was independently associated with 59-month CSS of 56,800 patients with colon cancer and had a 98.1% increased risk of cancer-specific mortality (HR =1.981, 95% CI =1.891--2.076, *P*\<0.001; [Table 1](#t1-cmar-10-2303){ref-type="table"}). Moreover, other factors identified as independent protective factors included lower TNM stage, sigmoid colon, surgery status, adenocarcinoma histology, and later age of diagnosis. A multivariable Cox analysis was also conducted in patients with nonmetastatic colon cancer (n=50,259) selected from the overall cohort. It once again confirmed that the P1-stage was independently associated with an increased risk of CSS (HR =2.315, 95% CI =2.172--2.467, *P*\<0.001; [Table S2](#SD2-cmar-10-2303){ref-type="supplementary-material"}) and showed a 131.5% increased risk of cancer-specific mortality in patients with nonmetastatic colon cancer (higher than that in the overall cohort), indicating that the prognostic prediction efficacy of P-stage improved in patients with AJCC stage I--III colon cancer.

Prognostic prediction of P--TNM stage: combination of P-stage and AJCC TNM staging system
-----------------------------------------------------------------------------------------

The survival curves of all P--TNM stage (AJCC TNM staging system combined with P-stage) were used to analyze the prognostic prediction of the P--TNM stage in the overall cohort (n=56,800; [Figure 3A--C](#f3-cmar-10-2303){ref-type="fig"}). As expected, all P0-stage patients showed a statistically significant increase in the 59-month CSS compared with the P1-stage patients (*P*\<0.001) in the respective AJCC TNM stages. Moreover, as [Figure 3A--C](#f3-cmar-10-2303){ref-type="fig"} also shows, an increased or similar 59-month CSS of stage P0--TNM patients compared with stage P1--TNM patients with higher AJCC stages was observed. A decreased CSS was also found in stage I--P1 patients compared with stage IIIA--P0 or IIA--P0 patients (*P*\<0.001), stage IIIA--P1 patients compared with stage IIA--P0 patients (*P*\<0.001), stage IIB--P1 patients compared with stage IIIB--P0 or IIC--P0 patients (*P*\<0.001), stage IIIB--P1 patients compared with stage IIC--P0 patients (*P*\<0.001), and stage IIC--P1 patients compared with stage IIIC--P0 patients (*P*\<0.001). Thus, a considerable overlap existed between the Kaplan--Meier survival curves of adjacent AJCC TNM stages. The Kaplan--Meier survival curves of stages I--P0, I--P1, II--P0, II--P1, III--P0, and III--P1 also showed that the P0-stage patients had a statistically significant increase in the 59-month CSS compared with the P1-stage patients (*P*\<0.001) in the respective AJCC TNM stages ([Figure 3D](#f3-cmar-10-2303){ref-type="fig"}). It was thus easily found that stage III--P0 had no significant difference from stage IIIA--P1 ([Figure S1](#SD1-cmar-10-2303){ref-type="supplementary-material"}). [Figure 4](#f4-cmar-10-2303){ref-type="fig"} shows that Kaplan--Meier survival curves of different TNM stages.

Multivariate Cox regression analyses were used to compare the HRs of each AJCC TNM stage and P--TNM stages. The 59-month CSS was also assigned to each P--TNM stage and TNM stage. Consistent with the Kaplan--Meier survival curves, stage P0--TNM patients showed increased 59-month CSS rates and decreased HRs compared with the respective P1--TNM stages ([Table 2](#t2-cmar-10-2303){ref-type="table"}). Also, HRs of several stage P1--TNM patients exceeded those with stage P0--TNM, and even those with higher conventional AJCC TNM stages. The cancer-specific mortality was higher in stage I--P1 patients (HR =3.390, 95% CI =2.775--4.141) compared with stage IIA--P0 (HR =2.048, 95% CI =1.706--2.457) or IIIA--P0 patients (HR =1.445, 95% CI =1.031--2.023), stage IIIA--P1 patients (HR =5.721, 95% CI =4.192--7.808) compared with stage IIA--C0 or IIIB--P0 patients (HR =4.836, 95% CI =4.106--5.696), stage IIB--P1 patients (HR =11.180, 95% CI =9.159--13.646) compared with stage IIIB--P0 or IIC--P0 patients (HR =6.149, 95% CI =4.229--8.940), stage IIIB--P1 patients (HR =10.571, 95% CI =9.077--12.311) compared with stage IIC--P0 patients, and stage IIC--P1 patients (HR =15.022, 95% CI =12.395--18.207) compared with stage IIIC--P0 (HR =11.304, 95% CI =9.434--13.543) patients. This stage migration indicated that the P--TNM stage had a more accurate prognostic prediction than the TNM stage after the combination with P-stage. Alternatively, the P1-stage had an upstage effect that P1 patients presented higher risk of cancer-specific mortality than those P0 patients with higher TNM stages in most patients with colon cancer. The prognostic prediction efficacy was even stronger in patients with nonmetastatic colon cancer.

Prognosis of N-stage combined with P-stage
------------------------------------------

Multivariate Cox regression analyses were also conducted in patients with nonmetastatic colon cancer to compare the HRs of each N-stage (N0, N1, N2a, and N2b) before and after the combination of P-stage, and the 59-month CSS was also assigned to each P--N stage and N-stage ([Table 3](#t3-cmar-10-2303){ref-type="table"}). The stage N--P0 patients showed increased 59-month CSS rates and lower HRs compared with the respective stage N--P1 patients. [Table 3](#t3-cmar-10-2303){ref-type="table"} also shows that the number of stage N--P1 patients exceeded the number of N--P0 stage patients with the higher N stages. The cancer-specific mortality was higher in the N0--P1 stage patients (HR =2.523, 95% CI =2.241--2.817) compared with N1--P0 patients (HR =1.964, 95% CI =1.705--2.263), stage N1--P1 patients (HR =4.541, 95% CI =4.009--5.143) compared with stage N2a--P0 patients (HR =2.870, 95% CI =2.356--3.496), and stage N2a--P1 patients (HR =6.607, 95% CI =5.650--7.726) compared with stage N2b--P0 patients (HR =5.006, 95% CI =4.101--6.111). The aforementioned results indicated that P1 patients had a significantly worse prognosis than those with N1-, N2a-, and even N2b-stage.

Discussion
==========

The AJCC TNM staging system is the most commonly used algorithm in the clinical practice of colon cancer. However, the TNM stage considers only the invasion extent of primary tumor (T-stage), lymph node status (N-stage), and distant spread (M-stage) without considering other factors that influence the prognosis of colon cancer.[@b15-cmar-10-2303] This was not perfect for prognostic prediction, although several modifications in the past years had improved its predictive ability. AJCC had issued a request for staging methods based on other available information beyond the conventional TNM staging system.[@b2-cmar-10-2303] Therefore, a more comprehensive staging that included other demographic and clinicopathologic variables known to impact the survival was urgently needed.

Previous studies showed that age at diagnosis,[@b3-cmar-10-2303],[@b6-cmar-10-2303]--[@b9-cmar-10-2303] tumor grade,[@b4-cmar-10-2303],[@b10-cmar-10-2303],[@b11-cmar-10-2303] and tumor size[@b5-cmar-10-2303],[@b12-cmar-10-2303],[@b13-cmar-10-2303] had a strong correlation with the prognosis of colon cancer. For example, Saha et al[@b13-cmar-10-2303] found that the 5-year overall survival was 66%, 52%, 46%, and 41% in the subgroups with tumor sizes of 0--2, \>2--4, \>4--6, and \>6 cm, respectively. In 2012, Patel et al[@b7-cmar-10-2303] reported that the oldest age group (\>80 years old) had a 238% increased overall mortality compared with the youngest age group (18--49 years). In 2011, Weiser et al[@b2-cmar-10-2303] developed prognostic models (incorporating T-stage, N-stage, numbers of positive lymph nodes, numbers of total lymph nodes, age, gender, and tumor grade) that outperformed the current AJCC TNM staging system. Considering that HRs of male and female patients with colon cancer were not significantly different ([Table 1](#t1-cmar-10-2303){ref-type="table"}) and the numbers of positive lymph nodes and total lymph nodes had some overlap with the N-stage, these were not included in the P--TNM stage in this study.

In the present large, representative, population-based study, the AJCC TNM staging system was extended to include patient- and tumor-related variables of age of diagnosis, tumor grade, and tumor size, which are routinely available from the SEER database, and the 59-month CSS of each P--TNM stage, and thus a combination of the newly proposed P-stage and TNM stage was analyzed. The present study confirmed that all P1-stage patients had a statistically significant increase in mortality compared with the P0-stage patients with the same TNM stage. Also, the 98.1% increased HR in the overall cohort and 131.5% increased HR in the patients with nonmetastatic colon cancer also proved that the P1-stage greatly increased the 59-month cancer-specific mortality. The study also showed that several P1--TNM stages even exceeded the P0--TNM stages with higher AJCC TNM stages. The better prognosis of patients with several node-positive stages (stage IIIA--P0, IIIA--P1, or IIIB--P0) than that of several node-negative stages (stage IIC--P0, IIB--P0, IIA--P1, or IIA--P0) seemed to explain that a part of node-negative patients had a bad prognosis and that not all patients with node-positive status had a poor prognosis.[@b16-cmar-10-2303],[@b17-cmar-10-2303] Besides, this study showed that the P1-stage patients had a worse prognosis than the N1-, N2a-, and even N2b-stage patients, indicating that the P1-stage might be a more powerful predictor of worse prognosis compared with the node-positive status. Given the benefits of chemotherapy in node-positive patients,[@b18-cmar-10-2303],[@b19-cmar-10-2303] the P1-stage in this study was of great significance in indicating the use of chemotherapy. Also, in the analyses of P--TNM stage, it could be seen that the stage I (T1--T2N0M0)--P1 had a worse prognosis than stage IIIA (T1--T2N1M0)--P0. Considering almost the same in the T-stage (T1--T2), the P1-stage was once again proved to be stronger than the N1-stage for indicating a poor prognosis. However, in the clinical treatment today, stage IIIA patients are treated with adjuvant chemotherapy, while stage I patients are not.[@b20-cmar-10-2303] Therefore, this study took into account the possibility of under treatment in the TNM stage I colon cancer and over-treatment in the TNM stage IIIA colon cancer. Fortunately, the P-stage could distinguish well between stages I--P0 and I--P1 in the TNM stage I, and extremely well between stages IIIA--P0 and IIIA--P1 in the TNM stage IIIA (which also seemed to account for the better prognosis of TNM stage IIIA than stage IIIA).[@b2-cmar-10-2303],[@b21-cmar-10-2303] Moreover, toxicity and adverse events caused by adjuvant chemotherapy could result in significant patient morbidity.[@b22-cmar-10-2303] The present study suggested that the recommendation of reduced chemotherapy in stage IIIA--P0 deserves further investigation and prospective studies with the incorporation of the newly proposed P-stage. Therefore, this study strongly supported adding the P-stage into the conventional TNM staging system to generate a more refined, risk-adapted stage and thus guide the clinical treatment of colon cancer.

The adjuvant chemotherapy of TNM stage II has long been studied. At present, it has been widely accepted that patients with TNM stage II with any of high-risk factors, such as T4-stage, obstruction, perforation, poorly differentiated histology, \<12 lymph nodes, presence of lymphovascular or perineural invasion, or positive margins,[@b11-cmar-10-2303],[@b23-cmar-10-2303]--[@b26-cmar-10-2303] might be considered as candidates for adjuvant chemotherapy. In 2004, the American Society of Clinical Oncology recommended the use of adjuvant chemotherapy, especially for patients with high-risk TNM stage II colon cancer, despite adequate indirect evidence of benefit.[@b18-cmar-10-2303] The guidelines published by the European Society for Medical Oncology also recommend adjuvant chemotherapy for the high-risk stage II colon cancer despite insufficient scientific evidence supporting the effectiveness of adjuvant chemotherapy in this group of patients.[@b27-cmar-10-2303] However, in 2011, O'Connor et al[@b24-cmar-10-2303] reported that patients with stage II colon cancer with any high-risk factors (including obstruction, perforation, emergent admission, T4-stage, resection of fewer than 12 lymph nodes, and poor histology) did not get substantial survival benefit from adjuvant chemotherapy. In 2016, Verhoeff et al[@b28-cmar-10-2303] showed similar results after analyzing 4,940 patients with high-risk stage II colon cancer (pT4, poor/undifferentiated grade, emergency surgery, and/or \<10 evaluated lymph nodes). Given that high risks did not include the tumor size and age at diagnosis, this study considered that the P-stage might improve this situation.

Moreover, 1 distinct advantage of the simple and convenient P-stage was that the 3 prognostic factors (including age at diagnosis, tumor grade, and tumor size) were readily available and could even be specified preoperatively (tumor size known by colonoscopy, and then the colonoscopy biopsy to specify the tumor grade). After combining with the preoperative TNM stage, the P--TNM stage could be obtained, which is a more refined stage for better predicting the prognosis and guiding preoperative treatment for patients with colon cancer.

This study still had several limitations. First, the P--TNM stage did not take into account other prognostic factors, including the microsatellite instability status, treatment, carcinoembryonic antigen level, and so on. This could independently affect the survival,[@b19-cmar-10-2303],[@b29-cmar-10-2303],[@b30-cmar-10-2303] indicating that the P--TNM stage is not perfect and needs further improvement. Anatomical staging might be less important compared with the treatment factors (patients who received adjuvant therapy and the specific regimens of the therapy). Whether the stage IIIA--P0 had a good prognosis on account of biological characteristics (discriminated by P-stage) or treatment effect (adjuvant therapy) still remains unknown. However, the P1-stage might have a worse prognosis compared with the N2a- and N2b-stage in node-positive patients, and this study still recommended less chemotherapy in the stage IIIA--P0 patients. Second, the overall cohort incorporated 56,800 patients from the SEER database; hence, the sample size still needs to be enlarged. The longest follow-up time was only 59 months, not exceeding 5 years. Besides, the analyses were merely based on retrospective data. Therefore, prospective clinical studies concerning P-stage need to be carried out for more sensitive prognosis prediction compared with N-stage and prognosis discrimination of each TNM stage.

Conclusion
==========

The newly proposed P-stage, which is easily available even before performing operation on patients, explains the lack of clear ranking by stage in predicting outcomes using the conventional TNM stage. The present study strongly supported the incorporation of P-stage into the AJCC TNM stage (ie, the P--TNM stage) for a better approach to prognostication and, thus, more individualized risk-adaptive therapies.

Supplementary materials
=======================

###### 

Kaplan--Meier survival curves of II--P0 stage, II--P1 stage, III--P0 stage, IIIA--P1 stage, IIIB--P1 stage, and IIIC--P1 stage.

**Abbreviation:** CSS, cancer-specific survival.

###### 

Multivariable Cox regression analyses of all independent prognostic factors (including tumor size, tumor grade, and age of diagnosis)

  Covariate                  Variable                     Univariable analyses      Multivariable analyses                             
  -------------------------- ---------------------------- ------------------------- ------------------------ ------------------------- ---------
  Tumor grade                                                                       \<0.001                                            \<0.001
                             Grade I                      Reference                                          Reference                 
                             Grade II                     1.589 (1.437--1.758)      \<0.001                  1.059 (0.957--1.172)      0.270
                             Grade III                    3.416 (3.076--3.794)      \<0.001                  1.427 (1.282--1.588)      \<0.001
                             Grade IV                     4.073 (3.577--4.637)      \<0.001                  1.617 (1.417--1.845)      \<0.001
  Tumor size (cm)                                                                   \<0.001                                            \<0.001
                             ≤2                           Reference                                          Reference                 
                             \>2--4                       3.067 (2.749--3.422)      \<0.001                  1.228 (1.094--1.378)      0.001
                             \<4--6                       4.367 (3.919--4.866)      \<0.001                  1.312 (1.200--1.424)      \<0.001
                             \>6                          5.650 (5.068--6.300)      \<0.001                  1.453 (1.291--1.634)      \<0.001
  Age at diagnosis (years)                                                          \<0.001                                            \<0.001
                             ≤49                          Reference                                          Reference                 
                             \>49--64                     1.041 (0.956--1.134)      0.350                    1.307 (1.200--1.424)      \<0.001
                             \>64--79                     1.262 (1.163--1.371)      \<0.001                  1.875 (1.725--2.037)      \<0.001
                             \>79                         2.342 (2.157--2.544)      \<0.001                  3.911 (3.592--4.258)      \<0.001
  TNM-stage                                                                         \<0.001                                            \<0.001
                             I                            Reference                                          Reference                 
                             IIA                          2.318 (2.064--2.603)      \<0.001                  1.860 (1.646--2.101)      \<0.001
                             IIB                          6.099 (5.219--7.129)      \<0.001                  4.775 (4.065--5.611)      \<0.001
                             IIC                          8.359 (7.140--9.788)      \<0.001                  6.529 (5.536--7.702)      \<0.001
                             IIIA                         1.539 (1.224--1.934)      \<0.001                  1.647 (1.310--2.070)      \<0.001
                             IIIB                         4.902 (4.388--5.476)      \<0.001                  4.333 (3.854--4.872)      \<0.001
                             IIIC                         12.873 (11.490--14.422)   \<0.001                  10.942 (9.682--12.366)    \<0.001
                             IVA                          25.298 (22.685--28.213)   \<0.001                  23.230 (20.665--26.114)   \<0.001
                             IVB                          36.497 (32.647--40.801)   \<0.001                  32.078 (28.432--26.193)   \<0.001
  Tumor location                                                                    \<0.001                                            \<0.001
                             Cecum                        Reference                                          Reference                 
                             Ascending colon              0.827 (0.779--0.877)                               1.024 (0.964--1.087)      0.444
                             Hepatic flexure              0.876 (0.791--0.970)      0.011                    1.056 (0.953--1.170)      0.296
                             Transverse colon             0.899 (0.834--0.970)      0.006                    1.082 (1.003--1.167)      0.041
                             Splenic flexure              0.990 (0.886--1.106)      0.855                    1.100 (0.984--1.230)      0.093
                             Descending colon             0.784 (0.714--0.860)                               1.005 (0.915--1.104)      0.922
                             Sigmoid colon                0.698 (0.659--0.739)                               0.903 (0.851--0.958)      0.001
  Surgery                                                                           \<0.001                                            \<0.001
                             No surgery                   Reference                                          Reference                 
                             Surgery performed            0.138 (0.124--0.153)                               0.359 (0.322--0.402)      \<0.001
  Histology                                                                         \<0.001                                            0.001
                             Adenocarcinoma               Reference                                          Reference                 
                             Mucinous adenocarcinoma      1.265 (1.178--1.358)      \<0.001                  1.026 (0.954--1.103)      0.495
                             Signet ring cell carcinoma   2.957 (2.568--3.405)      \<0.001                  1.316 (1.139--1.521)      \<0.001
  Race                                                                              \<0.001                                            \<0.001
                             Black                        Reference                                          Reference                 
                             White                        0.865 (0.814--0.918)      \<0.001                  0.827 (0.778--0.879)      \<0.001
                             Other                        0.722 (0.658--0.792)      \<0.001                  0.697 (0.635--0.766)      \<0.001
                             Unknown                      0.227 (0.132--0.393)      \<0.001                  0.349 (0.202--0.603)      \<0.001
  Gender                                                                            0.164                                              0.031
                             Male                         Reference                                          Reference                 
                             Female                       1.030 (0.988--1.074)                               0.954 (0.914--0.996)      0.031
  Year of diagnosis                                                                 \<0.001                                            0.001
                             2010                         Reference                                          Reference                 
                             2011                         0.963 (0.911--1.019)      0.195                    0.945 (0.893--0.999)      0.047
                             2012                         0.938 (0.883--0.996)      0.038                    0.942 (0.886--1.001)      0.053
                             2013                         0.926 (0.863--0.993)      0.031                    0.931 (0.868--0.999)      0.047
                             2014                         0.787 (0.715--0.866)      \<0.001                  0.809 (0.735--0.891)      \<0.001

**Abbreviations:** CI, confidence interval; HR, hazard ratio.

###### 

Multivariable Cox regression analyses of all independent prognostic factors in nonmetastatic colon cancer patients

  Covariate           Reference        Variable                     CSS                             
  ------------------- ---------------- ---------------------------- ----------------------- ------- ---------
  P-stage             P0               P1                           2.315 (2.172--2.467)    0.032   \<0.001
  TNM-stage           I                IIA                          1.854 (1.646--2.089)    0.061   \<0.001
                                       IIB                          4.702 (4.012--5.511)    0.081   \<0.001
                                       IIC                          5.195 (4.422--6.103)    0.082   \<0.001
                                       IIIA                         1.710 (1.360--2.151)    0.117   \<0.001
                                       IIIB                         4.224 (3.769--4.733)    0.058   \<0.001
                                       IIIC                         9.974 (8.864--11.222)   0.060   \<0.001
  Tumor location      Cecum            Ascending colon              1.045 (0.967--1.129)    0.040   0.264
                                       Hepatic flexure              1.092 (0.961--1.241)    0.065   0.178
                                       Transverse colon             1.069 (0.968--1.181)    0.051   0.186
                                       Splenic flexure              1.148 (0.994--1.327)    0.074   0.061
                                       Descending colon             1.001 (0.884--1.133)    0.063   0.992
                                       Sigmoid colon                0.867 (0.801--0.938)    0.041   \<0.001
  Surgery             No surgery       Surgery performed            0.080 (0.067--0.097)    0.094   \<0.001
  Histology           Adenocarcinoma   Mucinous adenocarcinoma      1.013 (0.923--1.111)    0.047   0.788
                                       Signet ring cell carcinoma   1.411 (1.174--1.697)    0.094   \<0.001
  Race                Black            White                        0.892 (0.822--0.969)    0.042   0.007
                                       Other                        0.712 (0.627--0.807)    0.064   \<0.001
                                       Unknown                      0.259 (0.123--0.547)    0.380   \<0.001
  Gender              Male             Female                       1.040 (0.985--1.099)    0.028   0.159
  Year of diagnosis   2010             2011                         0.929 (0.863--1.001)    0.038   0.054
                                       2012                         0.931 (0.859--1.009)    0.041   0.083
                                       2013                         0.912 (0.831--1.001)    0.047   0.054
                                       2014                         0.786 (0.693--0.890)    0.064   \<0.001

**Abbreviations:** CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio; SE, standard error.
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![Flow diagram of patient population selected from the SEER database.\
**Abbreviations:** CRC, colorectal cancer; SEER, Surveillance, Epidemiology, and End Results.](cmar-10-2303Fig1){#f1-cmar-10-2303}

![Patient prognostic score in patients with colon cancer: risk stratifications.](cmar-10-2303Fig2){#f2-cmar-10-2303}

![Kaplan--Meier survival curves of patients based on the P--TNM staging system.\
**Notes: (A)** CSS of I--P0 stage, I--P1 stage, IIA--P0 stage, IIA--P1 stage, IIIA--P0 stage, and IIIA--P1 stage. **(B)** CSS of IIB--P0 stage, IIB--P1 stage, IIC--P0 stage, IIC--P1 stage, IIIB--P0 stage, and IIIB--P1 stage. **(C)** CSS of IIC--P0 stage, IIC--P1 stage, IIIC--P0 stage, IIIC--P1 stage, IV--P0 stage, and IV--P1 stage. **(D)** CSS of I--P0 stage, I--P1 stage, II--P0 stage, II--P1 stage, III--P0 stage, and III--P1 stage.\
**Abbreviation:** CSS, cancer-specific survival.](cmar-10-2303Fig3){#f3-cmar-10-2303}

![Kaplan--Meier survival curves of TNM staging system (including stage IIA, stage IIB, stage IIC, stage IIIA, stage IIIB, and stage IIIC).\
**Abbreviation:** CSS, cancer-specific survival.](cmar-10-2303Fig4){#f4-cmar-10-2303}

###### 

Multivariable Cox regression analyses of all independent prognostic factors

  Covariate           Reference        Variable                     CSS                               
  ------------------- ---------------- ---------------------------- ------------------------- ------- ---------
  P-stage             P0               P1                           1.981 (1.891--2.076)      0.024   \<0.001
  TNM-stage           I                IIA                          1.812 (1.611--2.037)      0.060   \<0.001
                                       IIB                          4.667 (3.989--5.461)      0.080   \<0.001
                                       IIC                          5.871 (5.005--6.888)      0.081   \<0.001
                                       IIIA                         1.579 (1.257--1.985)      0.117   \<0.001
                                       IIIB                         4.102 (3.669--4.586)      0.057   \<0.001
                                       IIIC                         9.946 (8.862--11.162)     0.059   \<0.001
                                       IVA                          20.291 (18.169--22.661)   0.056   \<0.001
                                       IVB                          27.039 (24.138--30.288)   0.058   \<0.001
  Tumor location      Cecum            Ascending colon              1.043 (0.982--1.107)      0.031   0.172
                                       Hepatic flexure              1.069 (0.965--1.184)      0.052   0.201
                                       Transverse colon             1.072 (0.994--1.157)      0.039   0.071
                                       Splenic flexure              1.024 (0.917--1.145)      0.057   0.672
                                       Descending colon             0.911 (0.830--1.000)      0.048   0.051
                                       Sigmoid colon                0.815 (0.769--0.865)      0.030   \<0.001
  Surgery             No surgery       Surgery performed            0.346 (0.309--0.386)      0.057   \<0.001
  Histology           Adenocarcinoma   Mucinous adenocarcinoma      1.003 (0.933--1.078)      0.037   0.942
                                       Signet ring cell carcinoma   1.441 (1.249--1.662)      0.073   \<0.001
  Race                Black            White                        0.947 (0.892--1.006)      0.031   0.077
                                       Other                        0.770 (0.701--0.845)      0.048   \<0.001
                                       Unknown                      0.356 (0.206--0.615)      0.279   \<0.001
  Gender              Male             Female                       1.050 (1.007--1.095)      0.021   0.022
  Year of diagnosis   2010             2011                         0.946 (0.894--1.001)      0.029   0.053
                                       2012                         0.937 (0.882--0.996)      0.031   0.036
                                       2013                         0.925 (0.862--0.992)      0.036   0.029
                                       2014                         0.782 (0.711--0.861)      0.049   \<0.001

**Abbreviations:** CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio; SE, standard error.

###### 

Prognosis of P-stage and P--TNM stage in colon cancer

  Stage                     59-month CSS rate (%)   Number of patients   CSS                               
  ------------------------- ----------------------- -------------------- ------------------------- ------- ---------
  AJCC TNM staging system                                                                                  
  I                         95.3                    12,753               1.00 (Reference)          --      --
  IIA                       88.2                    16,182               1.811 (1.610--2.036)      0.060   \<0.001
  IIB                       64.6                    1,637                4.658 (3.980--5.450)      0.080   \<0.001
  IIC                       66.3                    1,193                5.847 (4.984--6.859)      0.081   \<0.001
  IIIA                      90.0                    1,926                1.582 (1.259--1.988)      0.117   \<0.001
  IIIB                      73.9                    12,307               4.100 (3.667--4.584)      0.057   \<0.001
  IIIC                      48.0                    4,261                9.900 (8.821--11.111)     0.059   \<0.001
  IV                        16.4                    6,541                22.680 (20.381--25.239)   0.055   \<0.001
  TNM--P staging system                                                                                    
  I--P0                     96.8                    9,842                1.00 (Reference)          --      --
  I--P1                     90.1                    2,911                3.390 (2.775--4.141)      0.102   \<0.001
  IIA--P0                   92.6                    7,080                2.048 (1.706--2.457)      0.093   \<0.001
  IIA--P1                   84.7                    9,102                4.706 (4.023--5.505)      0.080   \<0.001
  IIB--P0                   67.7                    636                  6.553 (5.013--8.566)      0.137   \<0.001
  IIB--P1                   62.3                    1,001                11.180 (9.159--13.646)    0.102   \<0.001
  IIC--P0                   76.0                    285                  6.149 (4.229--8.940)      0.191   \<0.001
  IIC--P1                   62.9                    908                  15.022 (12.395--18.207)   0.098   \<0.001
  IIIA--P0                  92.1                    1,477                1.445 (1.031--2.023)      0.172   \<0.001
  IIIA--P1                  82.8                    449                  5.721 (4.192--7.808)      0.159   \<0.001
  IIIB--P0                  79.6                    6,132                4.836 (4.106--5.696)      0.084   \<0.001
  IIIB--P1                  68.2                    6,175                10.571 (9.077--12.311)    0.078   \<0.001
  IIIC--P0                  61.5                    1,522                11.304 (9.434--13.543)    0.092   \<0.001
  IIIC--P1                  40.1                    2,739                25.475 (21.831--29.728)   0.079   \<0.001
  IV--P0                    21.4                    2,653                32.658 (28.066--38.003)   0.077   \<0.001
  IV--P1                    12.9                    3,888                53.072 (45.817--61.476)   0.075   \<0.001

**Abbreviations:** AJCC, American Joint Committee on Cancer; CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio; SE, standard error.

###### 

Prognosis of N-stage combined with P-stage in nonmetastatic colon cancer

  Variable     59-month CSS rate (%)   Number of patients   CSS                              
  ------------ ----------------------- -------------------- ------------------------ ------- ---------
  N-stage                                                                                    
   N0          91.3                    28,935               1.00 (Reference)         --      --
   N1          80.9                    9,936                1.855 (1.709--2.013)     0.042   \<0.001
   N2a         68.8                    2,591                2.700 (2.412--3.022)     0.058   \<0.001
   N2b         54.5                    1,794                4.653 (4.179--5.180)     0.055   \<0.001
  N--P stage                                                                                 
   N0--P0      95.0                    16,922               1.000 (Reference)        --      --
   N0--P1      85.9                    12,013               2.513 (2.241--2.817)     0.058   \<0.001
   N1--P0      85.6                    5,474                1.964 (1.705--2.263)     0.072   \<0.001
   N1--P1      74.9                    4,462                4.541 (4.009--5.143)     0.064   \<0.001
   N2a--P0     74.6                    1,346                2.870 (2.356--3.496)     0.101   \<0.001
   N2a--P1     62.5                    1,245                6.607 (5.650--7.726)     0.080   \<0.001
   N2b--P0     67.0                    772                  5.006 (4.101--6.111)     0.102   \<0.001
   N2b--P1     44.9                    1,022                11.363 (9.803--13.172)   0.075   \<0.001

**Abbreviations:** CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio; SE, standard error.
